+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Brain Regulation of Renin Secretion Involves Central Histaminergic Neurons

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The possible involvement of histamine (HA) in the stress-induced increase in plasma renin activity (PRA) was investigated in male rats. Intracerebroventricular (ICV) infusion of histamine (HA; 3.8–60 µg) increased PRA dose-dependently, and the K<sub>d</sub> (dissociation konstant) of HA was estimated to approximately 30 µg. ICV infusion of HA (30 µg) as well as 5 min of restraint stress increased plasma renin activity (PRA) 2- and 3-fold, respectively (p < 0.01). These effects were abolished by prior ICV infusion of the H<sub>2</sub>-receptor antagonists cimetidine (100 µg) and ranitidine (125 µg) (p < 0.01), which reduced the PRA to subbasal levels (p < 0.05). When administered alone the H<sub>2</sub>-receptor antagonists had no effect on PRA. In contrast, the H<sub>1</sub>-receptor antagonist mepyramine (100 µg) increased the basal PRA level (p < 0.01) and slightly augmented the HA- and stress-induced increase in PRA (p < 0.05). HA as well as restraint stress increased the plasma levels of dopamine, norepinephrine and epinephrine almost 2-fold (p < 0.01). The effect of the two stimuli was prevented by prior ICV infusion of mepyramine or cimetidine (p < 0.01). Pretreatment with the β-adrenergic receptor blocker propranolol (7 mg/kg i.p.) abolished the HA-induced and inhibited by 70% the stress-induced PRA increase. The results indicate that histaminergic neurons participate in the cerebral regulation of renin secretion. The H<sub>2</sub>-receptor-mediated PRA-increasing effect of HA involves activation of sympathetic nerves. In addition, HA seems to exert a minor inhibiting effect on PRA via H<sub>1</sub>-receptors.

          Related collections

          Author and article information

          S. Karger AG
          03 April 2008
          : 52
          : 2
          : 175-180
          Institute of Medical Physiology C, The Panum Institute, University of Copenhagen, Denmark
          125570 Neuroendocrinology 1990;52:175–180
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article